Analyst picks & changes

Analyst picks & changes

Analyst picks & changes
Company Bank Analyst Coverage Opinion Wk chg 12/30 cls
Alnylam (ALNY) ThinkEquity Andrew McDonald Upgrade Buy (from accumulate) -1% $13.36
McDonald raised his target to $15 from $14. He said ALN-RSV01, an siRNA in Phase I testing for respiratory syncytial virus (RSV), could reach sales of more than $1B.
Amgen (AMGN) HSBC Gene Mack New Overweight -2% $78.86
Mack set a 24-month target of $114. He expects double-digit annual growth to 2010 for anemia drugs Aranesp and Epogen, neutropenia drugs Neulasta and Neupogen, and arthritis and psoriasis drug Enbrel.
Amylin (AMLN) Oppenheimer Cory Kasimov New Neutral

Read the full 1047 word article

How to gain access

Continue reading with a
two-week free trial.